{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:50:35Z","timestamp":1789437035265,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council of Australia","doi-asserted-by":"publisher","award":["APP1030528"],"award-info":[{"award-number":["APP1030528"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Novartis International"},{"name":"Mary Overton Early Career Fellowship"},{"name":"Australian Postgraduate Award"}],"content-domain":{"domain":["lrjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.leukres.2014.12.015","type":"journal-article","created":{"date-parts":[[2015,1,6]],"date-time":"2015-01-06T20:20:47Z","timestamp":1420575647000},"page":"380-387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma"],"prefix":"10.1016","volume":"39","author":[{"given":"Sally K.","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen Ying","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Fitter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luen B.","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.W.","family":"Zannettino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.leukres.2014.12.015_bib0170","first-page":"983","article-title":"Myeloma bone disease: pathogenesis and treatment","volume":"19","author":"Roodman","year":"2005","journal-title":"Oncology (Williston Park)"},{"issue":"13","key":"10.1016\/j.leukres.2014.12.015_bib0175","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","article-title":"Multiple myeloma bone disease: pathophysiology of osteoblast inhibition","volume":"108","author":"Giuliani","year":"2006","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.leukres.2014.12.015_bib0180","first-page":"5438","article-title":"Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo","volume":"63","author":"Farrugia","year":"2003","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.leukres.2014.12.015_bib0185","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.bbrc.2005.09.146","article-title":"Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease","volume":"338","author":"Heider","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"10.1016\/j.leukres.2014.12.015_bib0190","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1158\/0008-5472.CAN-04-1687","article-title":"Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients","volume":"65","author":"Zannettino","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2014.12.015_bib0195","article-title":"Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells","author":"Noll","year":"2013","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.leukres.2014.12.015_bib0200","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2141.2004.05084.x","article-title":"Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells","volume":"126","author":"Silvestris","year":"2004","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.leukres.2014.12.015_bib0205","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1046\/j.1365-2141.2003.04374.x","article-title":"Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease","volume":"122","author":"Silvestris","year":"2003","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.leukres.2014.12.015_bib0210","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1535-6108(03)00248-4","article-title":"Targeting the PI3K-Akt pathway in human cancer: rationale and promise","volume":"4","author":"Luo","year":"2003","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.leukres.2014.12.015_bib0215","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1182\/blood-2003-07-2187","article-title":"Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor alpha","volume":"103","author":"Abroun","year":"2004","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2014.12.015_bib0220","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1182\/blood.V96.8.2856","article-title":"Insulin-like growth factor I is a dual effector of multiple myeloma cell growth","volume":"96","author":"Ge","year":"2000","journal-title":"Blood"},{"issue":"42","key":"10.1016\/j.leukres.2014.12.015_bib0225","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1038\/sj.onc.1204833","article-title":"Biologic sequelae of interleukin-6 induced PI3-K\/Akt signaling in multiple myeloma","volume":"20","author":"Hideshima","year":"2001","journal-title":"Oncogene"},{"issue":"43","key":"10.1016\/j.leukres.2014.12.015_bib0230","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1038\/sj.onc.1205923","article-title":"Role of the phosphatidylinositol 3-kinase\/Akt and mTOR\/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma","volume":"21","author":"Pene","year":"2002","journal-title":"Oncogene"},{"issue":"5727","key":"10.1016\/j.leukres.2014.12.015_bib0235","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1126\/science.1107627","article-title":"Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation","volume":"308","author":"Kratchmarova","year":"2005","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.leukres.2014.12.015_bib0240","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1182\/blood-2007-07-104281","article-title":"Long-term imatinib therapy promotes bone formation in CML patients","volume":"111","author":"Fitter","year":"2008","journal-title":"Blood"},{"issue":"1\u20132","key":"10.1016\/j.leukres.2014.12.015_bib0245","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0014-5793(01)03236-7","article-title":"Inhibition of PI3K\/p70 S6K and p38 MAPK cascades increases osteoblastic differentiation induced by BMP-2","volume":"510","author":"Vinals","year":"2002","journal-title":"FEBS Lett"},{"issue":"1","key":"10.1016\/j.leukres.2014.12.015_bib0250","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/jcb.10503","article-title":"Phosphatidylinositol 3-kinase coordinately activates the MEK\/ERK and AKT\/NFkappaB pathways to maintain osteoclast survival","volume":"89","author":"Gingery","year":"2003","journal-title":"J Cell Biochem"},{"issue":"1","key":"10.1016\/j.leukres.2014.12.015_bib0255","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S8756-3282(01)00657-3","article-title":"The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation","volume":"30","author":"Lee","year":"2002","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.leukres.2014.12.015_bib0260","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1074\/jbc.M410480200","article-title":"Akt1\/Akt2 and mammalian target of rapamycin\/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors","volume":"280","author":"Sugatani","year":"2005","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.leukres.2014.12.015_bib0265","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/jbmr.85","article-title":"The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo","volume":"25","author":"Vandyke","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.leukres.2014.12.015_bib0270","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/JME-12-0003","article-title":"Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion","volume":"48","author":"Fitter","year":"2012","journal-title":"J Mol Endocrinol"},{"issue":"6","key":"10.1016\/j.leukres.2014.12.015_bib0275","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00109-011-0849-9","article-title":"Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone","volume":"90","author":"Zheng","year":"2012","journal-title":"J Mol Med (Berl)"},{"issue":"5","key":"10.1016\/j.leukres.2014.12.015_bib0280","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood.V93.5.1697","article-title":"Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease","volume":"93","author":"Dallas","year":"1999","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2014.12.015_bib0285","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant","volume":"102","author":"Blade","year":"1998","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.leukres.2014.12.015_bib0290","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1158\/0008-5472.CAN-11-2067","article-title":"Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1","volume":"72","author":"Fowler","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2014.12.015_bib0295","first-page":"191","article-title":"The 5T2MM murine model of multiple myeloma: maintenance and analysis","volume":"113","author":"Vanderkerken","year":"2005","journal-title":"Methods Mol Med"},{"issue":"3","key":"10.1016\/j.leukres.2014.12.015_bib0300","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.bone.2003.11.014","article-title":"Differential growth factor control of bone formation through osteoprogenitor differentiation","volume":"34","author":"Chaudhary","year":"2004","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.leukres.2014.12.015_bib0305","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1210\/endo.134.3.8119182","article-title":"Platelet-derived growth factor enhances bone cell replication, but not differentiated function of osteoblasts","volume":"134","author":"Hock","year":"1994","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.leukres.2014.12.015_bib0310","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1359\/jbmr.2002.17.2.257","article-title":"Platelet-derived growth factor BB secreted from osteoclasts acts as an osteoblastogenesis inhibitory factor","volume":"17","author":"Kubota","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.leukres.2014.12.015_bib0315","series-title":"Marrow stromal cell culture","first-page":"43","article-title":"Isolation and culture of human bone-derived cells","author":"Gundle","year":"1998"},{"issue":"2","key":"10.1016\/j.leukres.2014.12.015_bib0320","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/(SICI)1097-4644(199702)64:2<295::AID-JCB12>3.0.CO;2-I","article-title":"Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro","volume":"64","author":"Jaiswal","year":"1997","journal-title":"J Cell Biochem"},{"issue":"1","key":"10.1016\/j.leukres.2014.12.015_bib0325","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2002-12-3905","article-title":"Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease","volume":"102","author":"Oyajobi","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2014.12.015_bib0330","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1006\/bbrc.1998.9118","article-title":"Osteoblastic differentiation is enhanced by rapamycin in rat osteoblast-like osteosarcoma (ROS 17\/2.8) cells","volume":"249","author":"Ogawa","year":"1998","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261400410X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261400410X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T14:04:46Z","timestamp":1598623486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261400410X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S014521261400410X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2014.12.015","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2014.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}